BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21644050)

  • 1. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
    Holland WS; Tepper CG; Pietri JE; Chinn DC; Gandara DR; Mack PC; Lara PN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):185-94. PubMed ID: 21644050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
    Meng H; Jin Y; Liu H; You L; Yang C; Yang X; Qian W
    J Hematol Oncol; 2013 Feb; 6():18. PubMed ID: 23415012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition.
    Kearney AY; Fan YH; Giri U; Saigal B; Gandhi V; Heymach JV; Zurita AJ
    PLoS One; 2015; 10(8):e0135962. PubMed ID: 26313261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
    Petrella BL; Brinckerhoff CE
    Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.
    Gemmill RM; Zhou M; Costa L; Korch C; Bukowski RM; Drabkin HA
    Br J Cancer; 2005 Jun; 92(12):2266-77. PubMed ID: 15956968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma.
    Tanaka T; Torigoe T; Hirohashi Y; Sato E; Honma I; Kitamura H; Masumori N; Tsukamoto T; Sato N
    J Cancer Res Clin Oncol; 2014 Mar; 140(3):503-13. PubMed ID: 24477694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
    Cho DC; Cohen MB; Panka DJ; Collins M; Ghebremichael M; Atkins MB; Signoretti S; Mier JW
    Clin Cancer Res; 2010 Jul; 16(14):3628-38. PubMed ID: 20606035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases.
    Steiner P; Hora M; Stehlik J; Martinek P; Vanecek T; Petersson F; Michal M; Korabecna M; Travnicek I; Hes O
    Virchows Arch; 2013 Feb; 462(2):183-92. PubMed ID: 23296808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways.
    Son JY; Yoon S; Tae IH; Park YJ; De U; Jeon Y; Park YJ; Rhyu IJ; Lee BM; Chung KH; Lim JE; Lee SJ; Lee HW; Kwak JH; Kim HS; Choi HY
    Cancer Med; 2018 Oct; 7(10):5083-5095. PubMed ID: 30160042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
    Cho DC; Hutson TE; Samlowski W; Sportelli P; Somer B; Richards P; Sosman JA; Puzanov I; Michaelson MD; Flaherty KT; Figlin RA; Vogelzang NJ
    Cancer; 2012 Dec; 118(24):6055-62. PubMed ID: 22674198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
    Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
    Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
    Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
    Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
    Liu H; Li X; Duan Y; Xie JB; Piao XL
    J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
    Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
    BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways.
    Selvarajah J; Nathawat K; Moumen A; Ashcroft M; Carroll VA
    Cell Death Dis; 2013 Oct; 4(10):e865. PubMed ID: 24136229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.